NURS 6521 Final Exam
Advanced Pharmacology
165 Comprehensive Questions With Detailed Rationales
Walden University | Latest Update
Aligned with NURS 6521 Final Exam Course Objectives and NCLEX-RN
EXAM STRUCTURE SUMMARY
Total Questions: 165
Sections: 9
Cognitive Levels: 25% Recall | 55% Application | 20% Analysis
Question Type: 4-option multiple choice (A-D), one correct
Style: 80% Scenario-based | 20% Direct recall
Coverage Highlights
• Pharmacokinetics, pharmacodynamics, drug interactions, CYP450, pharmacogenomics
• Cardiovascular, endocrine, respiratory, anti-infective, CNS, GI/GU/musculoskeletal pharmacology
• Prescriptive authority, DEA schedules, PMP, adverse drug reporting, deprescribing
• Special populations: pediatric, geriatric, pregnancy, renal/hepatic impairment
,NURS 6521 Final Exam | Advanced Pharmacology | Walden University | 2026/2027 Latest Update
• Beers Criteria, polypharmacy, therapeutic drug monitoring
• Comprehensive rationales with prescriber-level clinical judgment
Walden University Graduate Nursing Program
Prepared for Advanced Pharmacology Final Examination Preparation
Z.ai - NURS 6521 Advanced Pharmacology Final Exam Page 2
,NURS 6521 Final Exam | Advanced Pharmacology | Walden University | 2026/2027 Latest Update
Section 1: Pharmacologic Foundations and Prescriptive Practice
(Q1-Q20)
Pharmacokinetics, Pharmacodynamics, Drug Interactions, Pharmacogenomics, & Prescriptive Authority
(Q1-Q20)
Q1: A 67-year-old female client with hypoalbuminemia (albumin 1.9 g/dL) is started on phenytoin, a highly
protein-bound medication. The advanced practice nurse (APRN) understands that the MOST appropriate clinical
action is to:
A. Increase the phenytoin dose to account for reduced protein binding.
B. Reduce the phenytoin dose or interpret free drug levels; hypoalbuminemia increases free (active) drug,
raising toxicity risk even when total phenytoin level appears 'therapeutic' (10-20 mcg/mL). [CORRECT]
C. Discontinue phenytoin and switch to levetiracetam.
D. Administer phenytoin with food to enhance albumin production.
Correct Answer: B
Rationale:
Phenytoin is highly protein-bound (~90%), and only free drug is pharmacologically active. In hypoalbuminemia (liver
disease, nephrotic syndrome, malnutrition, inflammation, older adults), free fraction rises—increasing pharmacologic
effect and toxicity risk even when the total phenytoin level appears therapeutic. The corrected therapeutic range =
observed level / [(0.9 × albumin) + 0.1] (Sheiner-Tozer equation). Free (unbound) phenytoin level (therapeutic 1-2
mcg/mL) is the most accurate measure in hypoalbuminemia. Reduce dose, monitor clinically, and consider free drug
level.
Q2: An APRN is prescribing a medication for a client with severe hepatic impairment (Child-Pugh C). The
medication is primarily metabolized by CYP3A4 with extensive first-pass effect. The APRN understands that:
A. Hepatic impairment increases first-pass metabolism, requiring dose increase.
B. Hepatic impairment reduces first-pass metabolism and CYP3A4 activity, increasing bioavailability
and reducing clearance—requiring dose reduction and/or extended dosing interval, with close
monitoring. [CORRECT]
C. Hepatic metabolism is not relevant to drug dosing.
D. Renal clearance will compensate for hepatic impairment.
Correct Answer: B
Rationale:
Severe hepatic impairment reduces: (1) first-pass metabolism (more bioavailable drug—lower oral doses needed); (2)
CYP450 enzyme activity (slower metabolism—prolonged half-life, accumulation); (3) plasma protein synthesis (lower
albumin—more free drug). Drug-specific dosing guidelines vary; consider alternative renally-cleared drugs when
possible. Child-Pugh score (A, B, C) guides hepatic dosing for some drugs. Monitor: LFTs, drug levels (where
applicable), clinical response, adverse effects. Avoid hepatotoxic drugs (e.g., high-dose acetaminophen, statins in
cirrhosis, amiodarone, methotrexate, isoniazid).
Q3: An APRN is treating a client with status epilepticus who is being switched from IV fosphenytoin to oral
phenytoin. The client's CYP2C9 genotype reveals a *3/*3 (poor metabolizer) variant. The APRN should:
Z.ai - NURS 6521 Advanced Pharmacology Final Exam Page 3
, NURS 6521 Final Exam | Advanced Pharmacology | Walden University | 2026/2027 Latest Update
A. Administer the standard phenytoin loading dose (300 mg) and maintenance dose (300 mg/day).
B. Reduce phenytoin dose by 25-50% and monitor levels more frequently; CYP2C9 poor metabolizers
have reduced phenytoin clearance, requiring lower doses to avoid toxicity (nystagmus, ataxia, cognitive
impairment). [CORRECT]
C. Switch to phenobarbital instead of phenytoin.
D. Administer phenytoin IV only.
Correct Answer: B
Rationale:
Phenytoin is metabolized primarily by CYP2C9 (with CYP2C19 minor). CYP2C9 poor metabolizers (*2, *3 variants,
especially *3/*3) have significantly reduced phenytoin clearance (30-50% lower maintenance doses typically required).
CPIC guidelines recommend dose reduction (25-50% for intermediate/poor metabolizers) and slower titration with
therapeutic drug monitoring. Phenytoin follows Michaelis-Menten (saturable) kinetics—small dose increases cause
disproportionate level increases—making genetic variants particularly impactful. Alternative antiseizure medications
(levetiracetam, lamotrigine, topiramate—not significantly CYP-dependent) are reasonable for poor metabolizers.
Q4: An APRN is starting azithromycin for community-acquired pneumonia in a client already taking atorvastatin
80 mg daily. The APRN should:
A. Continue both medications without changes.
B. Recognize macrolides (especially erythromycin/clarithromycin) inhibit CYP3A4, increasing statin
levels and myopathy/rhabdomyolysis risk—azithromycin has minimal CYP3A4 inhibition (preferred
macrolide), but consider statin dose review and educate client on muscle pain reporting; consider
temporary statin hold for high-intensity statins. [CORRECT]
C. Increase atorvastatin dose for synergistic effect.
D. Discontinue atorvastatin permanently.
Correct Answer: B
Rationale:
Macrolide antibiotics inhibit CYP3A4 to varying degrees: erythromycin and clarithromycin are STRONG inhibitors
(significant statin interaction—FDA contraindicates with simvastatin/lovastatin, increased myopathy/rhabdomyolysis);
azithromycin has MINIMAL CYP3A4 effect (preferred macrolide with statins). For clients needing macrolide +
high-intensity statin: choose azithromycin (preferred), or hold statin during macrolide course (especially for
clarithromycin or erythromycin). Simvastatin/lovastatin contraindicated with strong CYP3A4 inhibitors (itraconazole,
ketoconazole, clarithromycin, erythromycin, protease inhibitors, nefazodone). Educate client on muscle pain,
weakness, dark urine (rhabdomyolysis).
Q5: An APRN is prescribing warfarin to a client with a CYP2C9 *2/*3 genotype. The APRN understands that
this client will likely require:
A. Higher warfarin doses to achieve therapeutic INR.
B. Lower warfarin doses (typically 20-40% reduction) and slower titration; CYP2C9 *2 and *3 variants
reduce warfarin clearance, increasing INR and bleeding risk—FDA warfarin labeling includes CYP2C9
dosing recommendations. [CORRECT]
C. Standard warfarin doses (5-10 mg/day).
D. Alternative anticoagulant only.
Correct Answer: B
Rationale:
Warfarin's more potent S-enantiomer is metabolized by CYP2C9. CYP2C9 *2 (R144C) and *3 (I359L) variants reduce
enzyme activity—*2 by ~30-40%, *3 by ~80-90%. Clients with *2/*3 genotype (compound heterozygous) require
Z.ai - NURS 6521 Advanced Pharmacology Final Exam Page 4
Advanced Pharmacology
165 Comprehensive Questions With Detailed Rationales
Walden University | Latest Update
Aligned with NURS 6521 Final Exam Course Objectives and NCLEX-RN
EXAM STRUCTURE SUMMARY
Total Questions: 165
Sections: 9
Cognitive Levels: 25% Recall | 55% Application | 20% Analysis
Question Type: 4-option multiple choice (A-D), one correct
Style: 80% Scenario-based | 20% Direct recall
Coverage Highlights
• Pharmacokinetics, pharmacodynamics, drug interactions, CYP450, pharmacogenomics
• Cardiovascular, endocrine, respiratory, anti-infective, CNS, GI/GU/musculoskeletal pharmacology
• Prescriptive authority, DEA schedules, PMP, adverse drug reporting, deprescribing
• Special populations: pediatric, geriatric, pregnancy, renal/hepatic impairment
,NURS 6521 Final Exam | Advanced Pharmacology | Walden University | 2026/2027 Latest Update
• Beers Criteria, polypharmacy, therapeutic drug monitoring
• Comprehensive rationales with prescriber-level clinical judgment
Walden University Graduate Nursing Program
Prepared for Advanced Pharmacology Final Examination Preparation
Z.ai - NURS 6521 Advanced Pharmacology Final Exam Page 2
,NURS 6521 Final Exam | Advanced Pharmacology | Walden University | 2026/2027 Latest Update
Section 1: Pharmacologic Foundations and Prescriptive Practice
(Q1-Q20)
Pharmacokinetics, Pharmacodynamics, Drug Interactions, Pharmacogenomics, & Prescriptive Authority
(Q1-Q20)
Q1: A 67-year-old female client with hypoalbuminemia (albumin 1.9 g/dL) is started on phenytoin, a highly
protein-bound medication. The advanced practice nurse (APRN) understands that the MOST appropriate clinical
action is to:
A. Increase the phenytoin dose to account for reduced protein binding.
B. Reduce the phenytoin dose or interpret free drug levels; hypoalbuminemia increases free (active) drug,
raising toxicity risk even when total phenytoin level appears 'therapeutic' (10-20 mcg/mL). [CORRECT]
C. Discontinue phenytoin and switch to levetiracetam.
D. Administer phenytoin with food to enhance albumin production.
Correct Answer: B
Rationale:
Phenytoin is highly protein-bound (~90%), and only free drug is pharmacologically active. In hypoalbuminemia (liver
disease, nephrotic syndrome, malnutrition, inflammation, older adults), free fraction rises—increasing pharmacologic
effect and toxicity risk even when the total phenytoin level appears therapeutic. The corrected therapeutic range =
observed level / [(0.9 × albumin) + 0.1] (Sheiner-Tozer equation). Free (unbound) phenytoin level (therapeutic 1-2
mcg/mL) is the most accurate measure in hypoalbuminemia. Reduce dose, monitor clinically, and consider free drug
level.
Q2: An APRN is prescribing a medication for a client with severe hepatic impairment (Child-Pugh C). The
medication is primarily metabolized by CYP3A4 with extensive first-pass effect. The APRN understands that:
A. Hepatic impairment increases first-pass metabolism, requiring dose increase.
B. Hepatic impairment reduces first-pass metabolism and CYP3A4 activity, increasing bioavailability
and reducing clearance—requiring dose reduction and/or extended dosing interval, with close
monitoring. [CORRECT]
C. Hepatic metabolism is not relevant to drug dosing.
D. Renal clearance will compensate for hepatic impairment.
Correct Answer: B
Rationale:
Severe hepatic impairment reduces: (1) first-pass metabolism (more bioavailable drug—lower oral doses needed); (2)
CYP450 enzyme activity (slower metabolism—prolonged half-life, accumulation); (3) plasma protein synthesis (lower
albumin—more free drug). Drug-specific dosing guidelines vary; consider alternative renally-cleared drugs when
possible. Child-Pugh score (A, B, C) guides hepatic dosing for some drugs. Monitor: LFTs, drug levels (where
applicable), clinical response, adverse effects. Avoid hepatotoxic drugs (e.g., high-dose acetaminophen, statins in
cirrhosis, amiodarone, methotrexate, isoniazid).
Q3: An APRN is treating a client with status epilepticus who is being switched from IV fosphenytoin to oral
phenytoin. The client's CYP2C9 genotype reveals a *3/*3 (poor metabolizer) variant. The APRN should:
Z.ai - NURS 6521 Advanced Pharmacology Final Exam Page 3
, NURS 6521 Final Exam | Advanced Pharmacology | Walden University | 2026/2027 Latest Update
A. Administer the standard phenytoin loading dose (300 mg) and maintenance dose (300 mg/day).
B. Reduce phenytoin dose by 25-50% and monitor levels more frequently; CYP2C9 poor metabolizers
have reduced phenytoin clearance, requiring lower doses to avoid toxicity (nystagmus, ataxia, cognitive
impairment). [CORRECT]
C. Switch to phenobarbital instead of phenytoin.
D. Administer phenytoin IV only.
Correct Answer: B
Rationale:
Phenytoin is metabolized primarily by CYP2C9 (with CYP2C19 minor). CYP2C9 poor metabolizers (*2, *3 variants,
especially *3/*3) have significantly reduced phenytoin clearance (30-50% lower maintenance doses typically required).
CPIC guidelines recommend dose reduction (25-50% for intermediate/poor metabolizers) and slower titration with
therapeutic drug monitoring. Phenytoin follows Michaelis-Menten (saturable) kinetics—small dose increases cause
disproportionate level increases—making genetic variants particularly impactful. Alternative antiseizure medications
(levetiracetam, lamotrigine, topiramate—not significantly CYP-dependent) are reasonable for poor metabolizers.
Q4: An APRN is starting azithromycin for community-acquired pneumonia in a client already taking atorvastatin
80 mg daily. The APRN should:
A. Continue both medications without changes.
B. Recognize macrolides (especially erythromycin/clarithromycin) inhibit CYP3A4, increasing statin
levels and myopathy/rhabdomyolysis risk—azithromycin has minimal CYP3A4 inhibition (preferred
macrolide), but consider statin dose review and educate client on muscle pain reporting; consider
temporary statin hold for high-intensity statins. [CORRECT]
C. Increase atorvastatin dose for synergistic effect.
D. Discontinue atorvastatin permanently.
Correct Answer: B
Rationale:
Macrolide antibiotics inhibit CYP3A4 to varying degrees: erythromycin and clarithromycin are STRONG inhibitors
(significant statin interaction—FDA contraindicates with simvastatin/lovastatin, increased myopathy/rhabdomyolysis);
azithromycin has MINIMAL CYP3A4 effect (preferred macrolide with statins). For clients needing macrolide +
high-intensity statin: choose azithromycin (preferred), or hold statin during macrolide course (especially for
clarithromycin or erythromycin). Simvastatin/lovastatin contraindicated with strong CYP3A4 inhibitors (itraconazole,
ketoconazole, clarithromycin, erythromycin, protease inhibitors, nefazodone). Educate client on muscle pain,
weakness, dark urine (rhabdomyolysis).
Q5: An APRN is prescribing warfarin to a client with a CYP2C9 *2/*3 genotype. The APRN understands that
this client will likely require:
A. Higher warfarin doses to achieve therapeutic INR.
B. Lower warfarin doses (typically 20-40% reduction) and slower titration; CYP2C9 *2 and *3 variants
reduce warfarin clearance, increasing INR and bleeding risk—FDA warfarin labeling includes CYP2C9
dosing recommendations. [CORRECT]
C. Standard warfarin doses (5-10 mg/day).
D. Alternative anticoagulant only.
Correct Answer: B
Rationale:
Warfarin's more potent S-enantiomer is metabolized by CYP2C9. CYP2C9 *2 (R144C) and *3 (I359L) variants reduce
enzyme activity—*2 by ~30-40%, *3 by ~80-90%. Clients with *2/*3 genotype (compound heterozygous) require
Z.ai - NURS 6521 Advanced Pharmacology Final Exam Page 4
